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Objective: Verbal information accompanying administration of a drug has 
been shown to modulate treatment outcome, in both positive and negative directions. 
If drug effects alter as a function of verbal suggestions, negative information may 
potentially abolish or even reverse treatment effects. To test whether nocebo 
information can reverse the effect of a drug, we investigated how such information 
modified the effect of a local anesthetic cream (Emla) on heat pain. Based on 
previous research, we further hypothesized that there would be an increase in 
negative emotions in the form of elevated levels of sympathetic arousal and stress in 
the groups receiving nocebo information. Method: Onehundredandfifty healthy 
volunteers (76 females) participated in a Six-Condition X Six-Trial between-subjects 
design, whereby heat pain was induced to the right volar forearm. Pain intensity was 
rated on a 10-mm visual analogue scale (COVAS), and negative emotional activation 
was assessed by skin conductance level (SCL), subjective stress ratings and systolic 
blood pressure measurements. Results: Nocebo information about the effect of Emla 
reversed its analgesic properties into hyperalgesia. The nocebo hyperalgesic response 
was accompanied by increased SCL and subjective stress, which indicates that the 
negative information about the effect of the cream led to increased psychological and 
sympathetic arousal. Conclusions: Negative information produced the opposite 
response of the intended effect of an anesthetic cream. The notion that mental 
processes overrode the biological effects of a pharmacologically based analgesic 
treatment may have important implications for clinical practice. 
Keywords: Drug Information, Nocebo hyperalgesia, Expectations, Pain, 
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Can Drug-Related Information Reverse the Effects of a Local Anesthetic Cream? An 
Investigation into the Nocebo Hyperalgesic Response 
 
 
Several studies have shown that verbal information given prior to 
administration of a medical procedure or drug can significantly modulate treatment 
outcome in both positive and negative directions (Bingel et al., 2011; Flaten, 
Simonsen & Olsen, 1999). Since a drug`s pharmacodynamic profile is modulated by 
drug-related information, the possibility exists that negatively charged information 
may abolish or even reverse the effect of the treatment (Dworkin, Chen, LeResche & 
Clark, 1983). As pain and emotions are closely interlinked at the neuronal level, 
information suggesting pain intensification may be accompanied by an expectancy-
induced increase in negative emotions such as anxiety and stress (Pollo & Benedetti, 
2012; Flaten, Aslaksen, Lyby & Bjørkedal, 2011). The fact that adverse information 
about the effect of a drug may produce an opposite response of the intended drug 
effect has important relevance for clinical practice and the conveying of information 
regarding side effects or treatment-related risks (Colloca & Miller, 2011).  
 A placebo or nocebo may be defined as an inert compound or procedure that 
is intended to create a positive or negative expectation, respectively. The placebo 
response is the positive expectancy or conditioning-induced change in a person’s 
brain-body unit (e.g. symptom amelioration), and the nocebo response is the adverse 
one (e.g. symptom deterioration) (Colloca & Miller, 2011). When a reduction in pain 
occurs based on positive information regarding an inactive substance, this is termed 
placebo analgesia. Conversely, when negative information regarding an inert 
substance leads to an increase in pain, a nocebo hyperalgesic response has occurred 
(Flaten et al., 2006; Benedetti, Amanzio, Vighetti & Asteggiano, 2006).  
 Previous research has suggested that positive emotions reduce pain, whereas 
negative emotions increase pain. In a study by Rhudy, Williams, McCabe, Russell 
and Maynard (2007) positive and negative emotional valence was evoked by 
displaying photos from the Internal Affective Picture System. While the photo slides 
were presented, painful electric stimulations were delivered to the sural nerve of the 
ancle. Emotional activation was assessed by means of physiological recordings such 
as nociceptive flexion reflex magnitude (NFR), skin conductance level (SCL) and 
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heart rate (HR). In addition, subjective pain ratings were obtained. The NFR, SCL 
and HR are modulated by emotional processing (Rhudy et al., 2007), and the SCL is 
a reliable physiological measurement of psychological and autonomic arousal (Armel 
& Ramachandran, 2003). The results suggested that the induction of positive 
emotions led to a reduction in both pain reports and physiological measurements, and 
that negative emotions led to pain increase (Rhudy et al., 2007).    
 Based on these findings it may be ventured that the placebo analgesic and 
nocebo hyperalgesic responses are mediated by emotional modulation. As for 
placebo analgesia, the logic is that the placebo manipulation or treatment reduces 
negative emotions (or induces positive emotions) which in turn leads to a decrease in 
pain perception (Aslaksen & Flaten, 2008). However, in order to assess causality 
between emotions and placebo responses, one must establish whether reduced 
emotional activation, i.e. in the form of decreased levels of stress is a cause of, or 
consequence of reduced pain. This can be done by recording emotions in the absence 
of pain. In a recent study by Aslaksen, Bystad, Vambheim and Flaten (2011) using 
experimental pain in a placebo procedure, subjective stress levels were obtained in 
the anticipatory periods when pain stimulation was absent. The results showed that 
administration of a placebo reduced stress, and that the reduction in stress levels 
could explain 17 and 26 per cent of placebo analgesia. The findings suggest that 
reduced stress and hence reduced negative emotional activation may be a mechanism 
for placebo responses in pain.        
 A logical extension of this hypothesis is that expectations of impending pain 
increase negative emotions like nervousness and fear, which in turn increase pain 
perception. Interestingly, at the molecular level the neurotransmission of the 
neuropeptide cholecystokinin (CCK) may play a pivotal role in the transformation of 
anxiety and stress into pain (Benedetti, Lanotte, Lopiano & Colloca, 2007). 
Experimental work by Rhudy and Meagher (2000) further illustrates the association 
between negative emotions and pain. In that study, healthy volunteers were assigned 
to either a fear condition, an anxiety condition or a neutral condition. Before and 
after the emotional inductions pain thresholds to radiant heat pain were tested. The 
findings revealed that anxiety led to increased pain reactivity, but that fear led to a 
decrease in pain reactivity. The results are in agreement with findings from animal 
studies, whereby anxiety has been shown to enhance pain and fear has been found to 
inhibit pain (stress-induced analgesia). A confirmation that the different conditions 
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produced the targeted emotional states was obtained by measuring skin conductance 
level and heart rate. Findings from this study lend further support to the view that 
negative emotional states modulate pain reactivity.      
 In sum, it seems that a reduction in stress and negative emotions reduces pain 
and could therefore be mechanisms mediating placebo analgesia. It may also be 
deducted that an increase in negative emotions such as anxiety and stress leads to 
enhanced pain perception, a possible mechanism behind nocebo hyperalgesia. To our 
knowledge, no previous studies have directly examined whether negative emotions 
increase as a result of nocebo-related negative information. This hypothesis was 
investigated in the present study.     
 Neurobiological correlates to the emotional modulation of pain are reflected 
in findings from brain imaging research. Imaging studies of the nocebo response 
show that nocebo hyperalgesia is accompanied by increased activity in the bilateral 
dorsal anterior cingulate cortex (dACC), insula, left frontal and parietal operculum, 
orbitofrontal cortex and hippocampus. Of particular interest is the involvement of the 
hippocampus, which is associated with anticipatory anxiety (Kong et al, 2008). 
Additionally, the entorhinal cortex of the left hippocampal formation has shown 
increased activity when painful stimulations followed the induction of negative 
emotions (Ploghaus et al., 2001). Overall, the findings are consistent with the 
hypothesis that the nocebo hyperalgesic response is predominantly produced through 
the (medial) affective-cognitive pain pathway, projecting through the thalamic nuclei 
to the ACC, insula and prefrontal cortices. Further support for this notion is that the 
lateral orbitofrontal cortex and dACC are areas associated with cognitive modulating 
of the emotional components of pain and the processing of affective aspects of pain 
(Kong et al., 2008), such as pain unpleasantness. The ACC, prefrontal cortex (PFC) 
and the insula are also activated during the anticipation of pain (Benedetti et al., 
2007).           
 Several studies have demonstrated that placebo analgesia is mediated by the 
activation of the opioidergic endogenous pain modulatory system (Pollo & Benedetti, 
2012; Benedetti et al., 2007). This top-down regulatory system consists of 
descending antinoceptive pathways extending from cognitive and affective cortical 
brain regions to the brain stem and spinal cord dorsal horns. Such findings have been 
confirmed in many experimental studies, including those employing brain imaging 
(Meissner et al., 2011). These studies establish that placebo analgesia involves the 
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activation of cingulo-frontal regions (rostral anterior cingulate cortex (rACC), insula, 
nucleus accumbens, dorsolateral prefrontal cortex (DLPFC), subcortical structures 
such as the periaqueductal gray (PAG), hypothalamus and amygdala (Meissner et al., 
2011) and the ipsilateral dorsal horn of the spinal cord.     
 Taken together, imaging and pharmacological studies indicate that placebo 
analgesia and nocebo hyperalgesia directly affect pain-related cognitive-affective 
neural activity in approximately the same areas of the brain, with opposite activation 
(Pollo & Benedetti, 2012). Accordingly, they illustrate that pain and emotions are 
closely interlinked at the neuronal level.      
 Apart from emotional modulation mediating the placebo analgesic and 
nocebo hyperalgesic responses, the most widely employed explanatory theory 
centers on cognitive top-down mechanisms such as expectations (Pollo & Benedetti, 
2012). Other commonly mentioned theories are conditioning and social observation 
(Meissner et al, 2011).        
 The open-hidden paradigm is an experimental approach which clearly 
demonstrates the importance of expectations in shaping the placebo and nocebo 
responses. In the open condition of a placebo procedure the patient is informed by a 
clinician that his or her symptoms will improve, inducing expectations of clinical 
benefit. In a nocebo procedure, the clinician informs the patient that the treatment has 
been discontinued, inducing expectations of symptom deterioration. A hidden 
administration in a placebo procedure consists of a continuation of treatment by a 
computer, whereby the participant is unaware of the fact that the treatment is being 
carried out. In this manner, no expectations are induced. In a nocebo intervention, a 
hidden administration means that the treatment has been interrupted without the 
patient`s knowledge of the discontinuation (Benedetti et al., 2007). The difference 
between the open and hidden treatment is thought to represent the placebo or nocebo 
component of the treatment, even though no inert substance has been administered. 
The reduced effectiveness of hidden treatments illustrates how knowledge about a 
treatment influence the therapeutic outcome. In a study by Colloca, Lopiano, Lanotte 
and Benedetti (2004) an open versus hidden nocebo procedure was performed in 
post-operative pain patients who underwent a treatment with morphine for 48 hours. 
In the open condition, the patients were informed that morphine infusion had been 
discontinued, and in the hidden condition, morphine was terminated without 
informing the patients. The results showed that more patients requested further 
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painkillers at 10 hours from the morphine interruption in the open group than in the 
hidden group, indicating that fear and negative expectations of pain relapse increased 
subjective sensations of pain in the open condition.     
 Experimental work by Dworkin et al. (1983) further illustrates the power of 
negative expectations on pain perception. In that study, the effect of 33% nitrous 
oxide on dental pulp pain was reversed from analgesia to hyperalgesia in healthy 
participants who expected an increase in pain level. In a more recent study by Bingel 
et al. (2011) similar findings emerged. Using functional magnetic resonance imaging 
(fMRI) in a within-subject design on healthy volunteers, they investigated how 
different expectancies were capable of altering the efficacy of the potent analgesic 
opioid agonist Remifentanil. The results showed that while expectations induced by 
positive verbal suggestions doubled the analgesic benefit of Remifentanil, negatively 
induced expectations abolished Remifentanil analgesia. To further support these 
findings, fMRI imaging showed that positive expectations were associated with 
activity in the endogenous pain modulatory system and negative expectations with 
modulated activity in the hippocampus. According to the authors, the results 
suggested that an individual’s expectations of the effects of a given drug can strongly 
influence its therapeutic efficacy and that these expectations are paralleled by 
significant changes in neural activity of core regions of the pain neuromatrix.  
 A study by Flaten et al. (1999) investigated whether positive and negative 
information regarding the muscle relaxant carisoprodol was able to induce 
physiological and psychological responses, and whether the information could 
modify the drug response. In order to test this either a placebo or carisoprodol was 
administered to half of the participants in three different groups. Drug administration 
was accompanied by verbal information stating it was either a muscle relaxant, a 
stimulant or with no information. When analyzing the results, the authors found that 
carisoprodol administered along with relaxant and with no information decreased 
subjective tension. Placebo administration along with information that it was as a 
stimulant increased tension. However, when carisoprodol was administered together 
with information suggesting it was a stimulant, subjective tension increased more 
compared to when the placebo was administered along with the same information. In 
fact, serum concentrations of carisoprodol increased in a parallel manner with 
reported tension. The findings indicate that the effects of the relaxing properties of 
carisoprodol was reversed by information suggesting it was a stimulant.  
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 Overall, these studies show that information accompanying drug 
administration might induce expectations that are able to override the 
pharmacological agents of the drug (Dworkin et al., 1983; Bingel et al., 2011). 
 In the present study, we investigated whether nocebo information could 
reverse the effect of 3 ml of the topical anesthetic EMLA cream© (AstraZeneca) on 
experimental heat pain in healthy volunteers. We studied the effects of drug 
information on EMLA and placebo cream under five different conditions: 
Nocebo/negative information before application of EMLA (nocebo EMLA 
condition), positive information before application of EMLA (EMLA standard info 
condition), positive information before application of an inert cream (placebo 
condition), nocebo/negative information before application of an inert cream (nocebo 
condition), and finally reduced information before application of EMLA (EMLA 
reduced info condition). A no information (natural history) condition was conducted 
as a control condition. The effects of these conditions were assessed on pain 
recordings and emotions.        
 Based on findings from previous research (Dworkin, 1983; Flaten et al., 
1999) we expected that nocebo information would override the analgesic effect of 
Emla, and turn analgesia into hyperalgesia in the nocebo EMLA group.  
 Furthermore, we hypothesized that there would be an increase in negative 
emotions after nocebo information, as assessed by self-reports and biological 
measurements (subjective stress, skin conductance response and blood pressure). 
 In the EMLA standard info condition and the placebo condition, we expected 

















Onehundredandfifty (N=150) healthy volunteers (76 females) between the 
ages of 19 and 40 years (Mean = 23,4, SD = 4,1) completed the experiment. 
Participants were recruited through announcements at campus of the University of 
Tromsø. Pregnant woman were not allowed to participate in the experiment. 
Participants who presently suffer from or had experienced any severe disease 
(including chronic pain), had cutaneous injuries on arms and hands or took 
prescribed medication (except birth control pills) were also excluded. All volunteers 
who were allowed to participate received a gift certificate worth 250 Norwegian 
kroner as compensation. The study was approved by the Regional Committee for 





A Six-Condition (nocebo EMLA condition, EMLA standard info condition, 
placebo condition, nocebo condition, EMLA reduced info condition) X Six-Trial 
(two pretests + four posttests) between-subjects design with repeated measures 
(ANOVA) was employed. The order of the conditions was balanced across 
participants, and the participants were randomized to the different conditions 
according to their participant number (n=25 per condition). All experimenters (2 
males, 2 females) were clinical psychology students with experience from 
experimental laboratory testing. The experiment was executed according to a double-
blind procedure in the five conditions where application of a placebo or EMLA was 
required. Since there was no application of placebo or EMLA cream in the natural 
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Pain Stimuli  
 
Pain was induced by contact-heat stimuli (30 x 30 mm aluminum contact 
thermode, Pathway System, Medoc, Israel) applied to the right volar forearm. The 
thermode had a baseline temperature of +32o C when applied to the arm, increasing 
to +48o C during the pain stimulations. The duration of pain stimuli was 15 seconds. 





The electrodes for the SCL were attached to the medial phalanges of the first 
and second finger of the left hand. SCL were recorded using two EL258 electrodes 
(Biopac Systems, Inc., USA). GEL101 (Biopac Systems, Inc.) electrode gel was 
used. The signal was recorded at 15 Hz with the Biopac Acqknowledge software 
(Biopac Systems Inc., USA) and analysed off-line with the Biopac Acqknowledge 
3.1 software. The SCL data was visually inspected offline to exclude artefacts. Blood 




Placebo cream and EMLA 
 
EMLA cream is the most widely used topical anesthetic, and is a 5% eutectic 
mixture of 25 mg/ml lidocaine and 25 mg/ml prilocaine in an oil-water emulsion 
cream. The application period of EMLA varies depending on the location of 
treatment, but multiple studies have shown that EMLA can produce dermal 
anesthesia 10-15 minutes after application, with a peak analgesic effect after a 
minimum of 60 minutes (Friedman, Mafong, Friedman & Geronemus, 2001). 
 The University hospital pharmacy at the University Hospital of Northern 
Norway produced tubes of EMLA© cream (AstraZeneca) and placebo cream (E45 
Cream; Crookes HealthCare, UK). The tubes were numbered according to a list of 
codes. The code list was created by the University hospital pharmacy, and was kept 
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by the supervisor of the study that did not participate directly in the experimental 
work. We chose the E45 placebo cream based on its similarity with EMLA both in 
color and consistency. In order to be certain that heating of the creams would be 
harmless, the pharmaceutical properties of EMLA and the E45 cream were assessed 
by a pharmacist at the University hospital pharmacy. The pharmacist concluded that 
a heating within the limits of the temperatures used in the present study would not 
inflict any kind of harm. 
 
 
Pain and Stress Measurements 
 
During each pain stimulus the participants reported pain intensity on a Visual 
Analogue Scale (0-10 (VAS) where 0 represented “no pain” and 10 represented 
“most intense pain imaginable”. The VAS was connected to the pathway system 
(COVAS, Medoc, Israel) and therefore reported pain intensity was electronically 
recorded after each pain stimulus. Subjective stress was measured by two adjective 
pairs from the Short Adjective Check List (SACL) (Mackay, Cox, Burrows & 
Lazzarini, 1978) in Norwegian translation (Appendix A). The adjective pairs were 
tensed-relaxed and nervous-calm. The SACL items were chosen for their high factor 
loadings on stress factors similar to previous studies (Aslaksen & Flaten, 2008; 





The order of conditions was randomized across participants. The experiment 
took place inside a steel cubicle (2.8 x 2.8 m) where the thermode, electrodes and 
blood pressure apparatus were positioned. The steel cubicle was placed inside a 
larger room containing the apparatus for control of experimental events and response 
recordings. The cubicle was shielded for sound and electricity, holding a constant 
temperature of 20o C. All instructions were given verbally to the participants. 
Upon arrival at the laboratory the participants signed the informed consent 
form (Appendix B). They then filled in personal information and the Norwegian 
translations of the Fear of Pain Questionnaire (FPQ-III) (McNeil & Rainwater, 1998) 
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(Appendix C) and the Positive and Negative Affect Scale (PANAS) (Watson, Clark, 
Tellegen, 1988) (Appendix D). The FPQ-III and the PANAS were recorded for use 
in another study, and the data from these questionnaires are therefore not included in 
the analysis in the present study. After completing the pen-and-paper measurements, 
the experimenters delivered the necessary information about the experimental 
procedure. They were then seated in a comfortable chair inside the cubicle. 
Subsequently blood pressure and subjective stress were measured and skin 
conductance electrodes attached to the medial phalanges of the first and second 
finger of the left hand. Thereafter, the experimenters instructed the participants in 
how to use the COVAS and attached the thermode to the volar right forearm, at 
dermatome corresponding to C8. The participants were then informed that the 
experiment would commence shortly.      
 Next, the experimenter stepped out of the steel cubicle and into the lager area 
of the laboratory and started the first two pain stimulations by activating the Pathway 
system (pretests). The time interval between pain stimulations was 60 seconds. Just 
before onset of the Pathway, skin conductance recordings were initiated. After the 
pretests, the experimenter delivered information regarding the cream, followed by 
application of the cream to a 5×5 cm location to the right volar forearm. Both the 
cream and information were selected according to instructions. The instructions were 
either: “The cream that will be applied to your arm reduces pain. The substance in 
the cream is used as a local anesthetic in many pain-reducing remedies, and is 
effective against heat pain” (the EMLA standard info condition and placebo 
condition) or “The cream that will be applied to your arm increases the effect of the 
heat pain and you will feel more pain. The substance in this cream is used in many 
medical remedies. Even though the pain feels more intense, the cream will not inflict 
any burn wounds” (the nocebo EMLA condition and nocebo condition) or “You will 
now receive a treatment with a medical cream. Because of the fact that we are 
interested in the pharmacological effect of this cream, we cannot provide information 
about which kind of medical properties it contains” (the EMLA reduced info 
condition). In the natural history condition no cream was applied and no information 
given.           
 Next, subjective stress and blood pressure were measured. Following a 16 
minutes application period the thermode was again attached to the forearm and the 
experimenter initiated the last four pain stimulations via the Pathway (posttests). 
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After the posttests, the final subjective stress and blood pressure measurements were 
obtained. The experimental procedure had a total duration of approximately one 










The statistical procedures were performed in SPSS 19.0 (SPSS, Chicago, IL, 
USA). Group differences and interactions were analyzed by general linear models 
(GLM), repeated measures ANOVA. In cases where Mauchly`s test indicated that the 
assumption of sphericity was violated, degrees of freedom were corrected using 
Greenhouse-Geisser corrections. Treatment effects for dependent variables were 
determined by subtracting the posttest score from the pretest score, and were 
analyzed by univariate GLMs. A significance level of .05 was employed. Significant 
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Descriptive statistics are presented in Table 1. None of the participants 
terminated any of the pain stimulations or the experiment as a whole.    











There was a significant main effect of trial on pain intensity, as pain changed 
from the first pre-test to the last post-test (F(3.41, 469.83) = 5.10, p < .001, η2 = 
.036). The interaction trial by group was significant (F(17.02, 469.83) = 8.89, p < 
.001, η2 = .24). Post hoc analyses using Fisher LSD revealed significantly lower pain 
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intensity in the EMLA condition compared the placebo condition (p = .025) , and a 
significantly higher pain intensity for the nocebo EMLA condition compared to the 
EMLA reduced info condition (p = .022) and the EMLA standard info condition (p = 
.004). There was a significant main effect of Gender (F(1, 138) = 33.82, p < .001, η2 
= .20), with an average of higher pain intensity for females compared to males, 
independent of conditions. Additionally, there was a significant main effect of group 
on VAS change scores (F(5, 144 ) = 11.38, p < .001, η2 = .28) (Figure 2). No other 





Figure 2. Pain intensity: Pain intensity was reported on a 10-mm VAS (COVAS). 
The figure shows treatment effect in each group (posttest - pretests). VAS pain 
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intensity values below zero indicates pain decrease, whereas VAS pain intensity 
values above zero shows pain increase. Standard errors are represented in the figure 





There was a significant main effect of trial on stress (F(1.81, 224.20) = 61.06, 
p < .001, η2 = .33) as stress changed from the first pretest to the last posttest. Post 
hoc analyses using Fisher LSD showed significantly higher levels of subjective stress 
in the nocebo EMLA condition compared to the EMLA reduced info condition (p = 
.006) and significantly higher levels of subjective stress in the nocebo condition 
compared to the EMLA reduced info condition (p = .014). There was a significant 
main effect of Gender (F(1, 124) = 6.17, p = .014, η2 = .047), with an average of 
higher levels of subjective stress for females compared to males, independent of 
conditions. There was no significant main effect of group on stress change scores 
(F(5, 138) = .78, p = .57, η2 = .08) (Figure 3), as stress decreased in all groups 
independent of treatment. No other main effects or interactions were significant in 
the subjective stress data. 
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Figure 3. Subjective stress: The figure shows the effect of treatment in each group 
(posttests – pretests). Standard errors are represented in the figure by the error bars 
attached to each column. 
 
 
Systolic blood pressure 
 
There was a significant main effect of trial on systolic blood pressure (F(1.79, 
216.04) = 15.44, p < .001, η2 = .11) as blood pressure changed from the first pre-test 
to the last post-test. The interaction systolic blood pressure and group was significant 
(F(8.93, 216.04) = 2.30, p = .022, η2 = .084). Post hoc analyses using Fisher LSD 
showed significantly higher systolic blood pressure in the nocebo condition 
compared to the EMLA reduced info condition (p = .005), the EMLA standard info 
condition (p = .008) and the placebo condition (p = .016). Additionally, there was a 
significant main effect of Gender (F(1, 121) = 37.37, p < .001, η2 = .24), with an 
average of higher systolic blood pressure for males compared to females, 
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independent of conditions. There was also a significant main effect of group on 
systolic blood pressure change scores (F(5, 138) = 2.78, p < .05, η2 = .09) (Figure 4). 







Figure 4. Systolic blood pressure: The figure shows the effect of treatment in each 
group (posttests – pretests). Standard errors are represented in the figure by the error 
bars attached to each column. 
 
 




Skin Conductance Level (SCL) 
 
 There were no significant effects in the repeated measures data on Skin 
conductance levels during pain (all F’s < 2,4), however, there was a significant main 
effect of group on SCL change scores (F(5, 134) = 21.87, p < .001, η2 =.45) (Figure 
5). Post hoc analyses using Fisher LSD revealed significantly higher SCL in the 
nocebo EMLA condition compared to the EMLA standard info condition (p < .001), 
the placebo condition (p < .001), the natural history condition (p < .001) and the 
EMLA reduced info condition (p < .001), and significantly higher SCL in the nocebo 
condition compared to the EMLA standard info condition (p < .001), the placebo 
condition (p < .001), natural history condition (p < .001) and EMLA reduced info 
condition (p < .001). There was significantly lower SCL in the EMLA standard info 
condition compared to the natural history condition (p = .026) and the EMLA 
reduced info condition (p < .001) and lower SCL in the placebo condition compared 








Figure 5. Skin conductance level. The figure displays treatment effect in each group 
(posttest - pretests). Values below zero indicate a decrease in skin conductance 
levels, while values above zero show an increase in skin conductance levels. 












The present study examined whether nocebo information could reverse the 
effect of 3 ml of the topical anesthetic Emla cream on experimental heat pain in 
healthy volunteers. We found that pain intensity reports in the nocebo EMLA 
condition were significantly higher compared to the EMLA reduced info condition 
and the EMLA standard info condition. The finding suggests that nocebo information 
about the effect of Emla reversed its analgesic properties into hyperalgesia. Hence, 
these data indicate that mental processes overrode the biological effect of a 
pharmacologically based treatment.       
 We further expected a decrease in levels of pain and negative emotions in the 
EMLA standard info condition and the placebo condition. We found significantly 
lower pain intensity reports in the EMLA standard info condition compared to the 
placebo condition. We also found a significant reduction in SCL in the EMLA 
standard info condition compared to the natural history condition and the EMLA 
reduced info condition. These results suggest that Emla had an analgesic effect, 
accompanied by a reduction in sympathetic arousal.    
 Finally, we hypothesized that there would be an increase in negative 
emotions after nocebo information, as assessed by self-reports and biological 
measurements. We found significantly higher levels of subjective stress and 
increased SCL in the groups receiving nocebo information, and increased systolic 
blood pressure in the nocebo condition compared to the EMLA reduced info 
condition, the EMLA standard info condition and the placebo condition. Increased 
SCL, systolic blood pressure and levels of subjective stress in the groups receiving 
nocebo information indicate increased psychological and sympathetic arousal, 
possibly due to the adverse information about the effect of Emla. Thus, nocebo 
information may have led to an expectancy-induced increase in negative emotions. 
The results also show that the hyperalgesic response exhibited in the nocebo EMLA 
condition was accompanied by increased SCL and subjective stress.   
The findings from the present study are consistent with previous research on 
the nocebo response, which suggests that the information given to patients may 
influence the therapeutic outcome negatively. For instance, Varelmann, Pancaro, 
Capiello and Camann (2011) tested whether the use of gentler words prior to 
administration of a local anesthetic affected pain reports and patient comfort in 
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women at term gestation requesting neuraxial analgesia. The women were 
randomized to either a placebo or a nocebo condition, whereby positive or negative 
information accompanied the local anesthetic skin injections, respectively. Following 
the injections, pain was assessed using a visual analogue scale. The results showed 
that whereas the use of gentler, more encouraging words led to a reduction in 
subjective pain reports, the use of harsher, nocebo-related words induced 
hyperalgesia.          
 Although clinically relevant pain such as injecting neuraxial analgesia is 
different from the experimental heat pain induced in the present study, our results 
extend the research by Varelmann et al. (2011) by showing that negative information 
was able to produce opposite responses of the intended effect of an analgesic 
treatment by turning analgesia into hyperalgesia. Accordingly, results from the 
present study are comparable with findings from experimental work by Dworkin et 
al. (1983) and Flaten et al. (1999), which demonstrate how mental processes can 
modify drug effect paradoxically. Moreover, our results resemble those obtained in a 
nocebo procedure by Colloca, Sigaudo and Benedetti (2008). In their study, verbal 
information of pain increase was provided to healthy volunteers before the 
administration of either tactile or low-intensity painful electrical stimulations. Pain 
intensity was reported on a Numerical Rating Scale ranging from 0 to 10, where 0 
represented no pain and 10 represented maximum imaginable pain. The results 
showed that the negative information was capable of turning tactile stimuli into pain 
and low-intensity painful stimulations into high-intensity pain. In a double-blind 
experiment by Luparello, Leist, Lourie and Sweet (1970) related findings emerged. 
Here, asthmatic patients were randomized to four conditions. In two groups, the 
participants were told that they received a bronchoconstrictor, when in reality they 
were administered a bronchodilator. Conversely, the other two groups were informed 
that they received a bronchodilator, but were provided with a bronchoconstrictor. 
The results showed that expectations induced by misinforming the participants about 
the medication reduced its biological effectiveness by 43% (bronchoconstrictor) and 
49% (bronchodilator).        
 Overall, it seems that in Dworkin et al. (1983) a reversal of the biological 
action of 33% of nitrous oxide was induced by negative information about drug 
effect, and in Flaten et al. (1999) the pharmacological agents of the muscle relaxant 
carisoprodol were overridden by contradicting information. Likewise, Luparello et 
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al. (1970) demonstrated how the biological properties of asthma medication were 
reversed by almost 50% after misinforming about its effect. Similarly, the effect of 
the opioid agonist Remifentanil was abolished by nocebo-related information (Bingel 
et al., 2011). In the present study, however, negative drug information regarding the 
effect of a local anesthetic cream reversed its analgesic agents into a nocebo 
hyperalgesic response. The fact that nocebo information produced antagonistic 
responses of the intended effects of a medical cream, has, to the best of our 
knowledge, not been previously demonstrated. 
The finding that negative information reversed the analgesic effects of Emla 
into hyperalgesia could have implications for clinical practice, where similar nocebo 
effects may occur after disclosure of drug related side effects. Some experiments 
have been explicitly designed to investigate the relation between informing patients 
about side effects, and the occurrence of such effects. In a study by Mondaini et al. 
(2007) patients with benign prostatic hyperplasia (BPH) were randomized to two 
different conditions; in one condition participants received information about 
possible sexually related side effects of 5 mg of Finasteride, an anti-BPH medication, 
and in the other condition no such information was disclosed. All patients were 
sexually active. Results showed that the group who was informed about sexually 
related dysfunctions reported a significantly higher number of side effects compared 
to the group with no information at a 6 to 12 months follow-up. In a study by Lang et 
al. (2005), warning patients about possible side effects or undesirable treatment 
outcomes led to significantly higher levels of reported pain and anxiety.   
 A similar question is how the results can be translated to clinical pain states. 
In the present study, nocebo-related information induced negative treatment 
expectancies within a matter of minutes. This is a short time-frame compared to the 
sometimes year-long experience of failure of analgesic treatments experienced by for 
instance chronic pain patients, whereby such adverse encounters may result in more 
robust negative expectations regarding future treatment outcomes. As such, our 
experimental data probably underestimate rather than overestimate similar effects in 
clinical practice. In addition, it is reasonable to assume that the experimental heat 
pain induced in our conditions is less susceptible to modulation by psychological 
factors than clinically relevant pain in which emotional and cognitive influences may 
be greater and the psychosocial context more complex (Bingel et al., 2011). 
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In the present study, we further found that nocebo-related information about 
the effects of Emla led to an increase in negative emotions. Similar results were 
obtained in experimental work by Johansen, Brox and Flaten (2003), which tested 
whether placebo and nocebo responses were mediated through a modulation of 
stress. In that study, participants were randomized to a placebo condition, nocebo 
condition or a natural history condition. In the placebo and nocebo conditions, the 
subjects were injected with a saline solution, and in the natural history condition, no 
injections were administered. When pain intensity reports reached “7” on a 10-point 
scale, information was delivered stating that the injection consisted of either a pain 
increasing (nocebo) or a pain reducing (placebo) substance. Subsequently, pain 
ratings and serum concentrations of cortisol and beta-endorphin were obtained. The 
results showed that cortisol secretions increased most in the nocebo condition, 
indicating elevated stress responses. However, pain levels were already at seven 
when the stress-inducing information was given, and an additional increase in pain 
could not be observed. This indicates that stress levels may have been increased prior 
to the provision of the negative information. As such, one can only speculate an 
assumption of a causal relation between nocebo information and negative emotions 
in the study.           
 In a different experiment by Schweiger and Parducci (1981) nocebo 
information that a (nonexistent) electrical current was being passed through the heads 
of healthy participants led to an increase in subjective pain reports. According to the 
authors, verbally induced psychological stress played a key role in mediating pain 
perception. In this particular study, on the other hand, the notion that the nocebo-
related information generated corresponding stress responses was based on 
subjective ratings of anxiety, in the absent of actually recording biological stress i.e. 
in the form of increased autonomic arousal or elevated blood pressure levels.  
Moreover, the literature indicating a causal association between nocebo 
information and negative emotional activation seems sparse. Thus, to our knowledge, 
it appears that the present study`s finding that nocebo-related information induced 
negative emotions as assessed by elevated levels of skin conductance responses, 
subjective stress and blood pressure has not been demonstrated in previous studies.
 Results from the present study additionally showed that the hyperalgesic 
response exhibited in the nocebo EMLA condition was accompanied by increased 
SCL and subjective stress. Based on these findings it may be hypothesized that a 
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possible course of mechanisms producing the results may have been that information 
regarding impending pain increased negative emotions like nervousness and fear, 
which in turn increased pain perception. As the anticipation of impending pain or 
pain increase can be highly stressful and anxiolytic, this process may have been 
mediated by the neurotransmission of cholecystokinin (CCK). CCK is a 
neuropeptide found in key structures of the descending pain modulatory system. It is 
involved in numerous physiological functions, but is especially central in the 
induction and persistence of anxiety and major depression and the induction of 
subjective and physiological stress (Hebb et al., 2005). In previous research by 
Benedetti et al. (2006), negative verbal suggestions accompanying the administration 
of an inert substance led to nocebo-induced hyperalgesia. The hyperalgesic response 
resulted in hyperactivity of the hypothalamic-pituary-adrenal (HPA) axis, as assessed 
by means of adrenocorticotropic hormone (ACTH) and cortisol plasma 
concentrations. Both HPA hyperactivity and nocebo hyperalgesia were antagonized 
by the benzodiazepine Diazepam, indicating that anxiety plays an important role in 
the nocebo response. By contrast, the administration of the CCK receptor antagonist 
Proglumide blocked nocebo hyperalgesia entirely, but seemed to have no effect on 
the HPA hyperactivity, suggesting an involvement of CCK in the hyperalgesic but 
not in the anxiety component of the nocebo response. Importantly, both Proglumide 
and Diazepam showed no analgesic properties on baseline pain, but acted only on the 
pain increase induced by the nocebo intervention.      
 In sum, these data suggest a close link between anxiety and nocebo 
hyperalgesia, in which CCK turns anxiety into pain. Interestingly, individuals with 
an elevated level of fear of pain could have a tendency for increased 
neurotransmission of CCK in situations where impending pain is anticipated. In a 
study by Lyby et al. (2009) the hypothesis was tested that fear of pain would be 
related to both higher pain intensity and stress and to a reduced placebo analgesic 
response. In that study, healthy volunteers were randomized to either a placebo or a 
natural history condition. In both conditions, heat pain was induced while measuring 
stress, arousal, pain intensity and pain unpleasantness, but in the placebo condition 
two capsules containing lactose was administered accompanied by information 
stating that it was a potent painkiller. Fear of pain was assessed by means of the Fear 
of Pain Questionnaire (FPQ-III). The results showed that higher scores in fear of pain 
were positively related to higher stress during the anticipation of pain and during 
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pain stimulations, and negatively related to placebo analgesia. Accordingly, findings 
from Lyby et al. (2009) may indicate that individuals high in fear of pain who 
respond with elevated levels of stress in painful situations exhibit stronger nocebo 
responses, mediated by increased CCK-ergic activity. In relation to the present study, 
such mechanisms may possibly have facilitated responding in the nocebo EMLA 
condition. 
The present study`s result that nocebo information led to hyperalgesia 
accompanied by increased sympathetic arousal in the nocebo EMLA condition may 
paradoxically have been mediated by the pharmacological properties of the Emla 
cream. In some cases, expectations of drug effects can be modulated if subjective 
sensations of the drug inform the individual that active medication has been 
administered. In placebo procedures this means that interoceptive or peripheral cues 
from the active agent may be interpreted in the direction of the positive information, 
thereby enhancing expectancies of pain relief and hence placebo responding. In 
experimental work by Bjørkedal and Flaten (2011), caffeine was used as an active 
substance to test whether side effects of drugs were able to increase both 
expectancies and placebo responses. In that study, healthy volunteers underwent 
painful laser stimulation before and after they received a drink with 0 or 4 mg/kg 
caffeine. Administration of the drink was crossed with verbal suggestions that it was 
either a painkiller or a placebo. The results showed that information that a painkiller 
had been administered increased the analgesic effects of caffeine compared to 
caffeine administration without drug information. This occurred on the bases of the 
interaction between the pharmacological properties of the caffeine combined with 
expectations. In relation to the present study, it may therefore be hypothesized that 
dermatological sensations produced by the Emla cream were interpreted in the 
direction of the negative information regarding its effect, thus leading to enhanced 
nocebo responding in the nocebo EMLA condition. Albeit plausible, further studies 
should be performed to unravel how negative expectations interact with the 
biological effects of pharmacologically based treatments.    
 In the present study, we found no significant reduction in pain intensity report 
in the placebo condition compared to the natural history condition, nor did we find a 
significant decrease in SCL, systolic blood pressure or subjective stress in the 
placebo condition compared to the natural history condition. A calibration of pain 
levels would potentially have induced a significant placebo response, and as such, 
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lack of calibration may represent a limitation of the present study. On the other hand, 
not calibrating can also be regarded a strength because it makes the findings more 
relevant for clinical settings.    
Since the possibility exists that the biological effects of the Emla cream was 
detectable, a potential extension of this hypothesis is that such effects may have led 
to an anticipation of pain reduction in participant who had previous experiences with 
similar analgesics. Hence, biological effects of Emla may have acted as a cue 
associated with the experience of treatment effects induced by resembling anesthetic 
creams in the past, thereby eliciting a conditioned response. According to such an 
interpretation, conditioning mechanisms may at least partly account for a 
significantly lower pain intensity report in the EMLA standard info condition 
compared to the placebo condition, and thus to some extent explain the lack of a 
placebo analgesic response in the present study. Based on such considerations, future 
studies investigating the effect of drug-related information on analgesic treatments 
should perhaps account for previous experience with analgesics.   
 In conclusion, results from the present study suggest that a consideration of 
the effects of negatively charged information regarding treatment effect is necessary 
especially in clinical situations, where nocebo-related responses represent a point of 
vulnerability. Providing the appropriate information about treatment outcome, 
potential side effects and the expected drug effect should therefore be considered an 
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Forespørsel om deltakelse i forskningsprosjektet 
Informasjon og effekten av legemiddel 
 
Bakgrunn og hensikt 
Formålet med denne studien er å teste hvordan informasjon om effekten av legemiddel 
påvirker smerteopplevelse ved behandling med smertedempende og 
smertesensitiverende krem.  
Vi ønsker å spørre friske personer mellom 18 og 40 år om å delta. Denne studien 
utføres ved Institutt for psykologi, UIT. 
 
Hva innebærer studien? 
Eksperimentet gjennomføres ved Institutt for psykologi, UIT. Eksperimentet innebærer 
at forsøkspersonene blir påført smerte ved hjelp av en datastyrt varmetermode som 
festes til armen. Kremene som benyttes er enten smertedempende krem med god 
smertedempende effekt mot varmesmerte, placebokrem, eller en krem som gjør huden 
mer sensitiv for smerte. Enkelte deltakere vil ikke få behandling med krem, og de vil 
inngå i kontrollgruppen i studien. Verken du som deltaker eller personen som 
gjennomfører eksperimentet vil ha eksakt kunnskap om kremen inneholder legemiddel 
eller er en placebokrem. 
Gjennom forsøket blir det målt subjektive og fysiologiske reaksjoner. 
Smertestimuleringene er relativt smertefulle, men ufarlige. Fysiologiske reaksjoner 
måles ved hjelp av skin conductance respons som måles ved hjelp av 
overflateelektroder. Varigheten på eksperimentet er ca 45 minutter.  
 
Mulige fordeler og ulemper 
Smertestimulus kan føre til at huden blir sensitiv og rød noen minutter etter forsøket. 
Dersom du får smertedempende krem, kan huden på armen oppleves som nummen i 
opptil 4 timer etter at forsøket er ferdig.  
Det er ingen personlige fordeler knyttet til eksperimentet, utover erfaring med hvordan 
eksperimentell forskning på mennesker kan utføres, samt hva som kan være med på å 
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forklare personlighetsmessige og emosjonelle forskjeller i smerte fra et psykologisk 
perspektiv.  
 
Hva skjer med prøvene og informasjonen om deg?  
Informasjonen som registreres om deg skal kun brukes slik som beskrevet i hensikten 
med studien. Alle opplysningene vil bli behandlet uten navn og fødselsnummer eller 
andre direkte gjenkjennende opplysninger. En kode knytter deg til dine opplysninger 
og prøver gjennom en navneliste. Det er kun autorisert personell knyttet til prosjektet 
som har adgang til navnelisten og som kan finne tilbake til deg. Det vil ikke være 
mulig å identifisere deg i resultatene av studien når disse publiseres.  
 
Frivillig deltakelse 
Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn 
trekke ditt samtykke til å delta i studien. Dersom du ønsker å delta, undertegner du 
samtykkeerklæringen på siste side. Om du nå sier ja til å delta, kan du senere trekke 
tilbake ditt samtykke uten at det påvirker din øvrige behandling. Dersom du senere 
ønsker å trekke deg eller har spørsmål til studien, kan du kontakte prosjektleder Per M. 
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Kapittel A- utdypende forklaring av hva studien 
innebærer 
Kriterier for deltakelse 
Vi søker etter friske studenter i alderen 18 – 50 år. De som deltar må ha god helse, 
ikke være gravid, ikke ha eller ha hatt alvorlige sykdommer eller bruke reseptbelagte 
legemiddel, med unntak av p-piller. Man kan heller ikke ha skader i huden på 
armene/hendene eller ha kronisk smertelidelse.  
Tidsskjema – hva skjer og når skjer det? 
Dersom du samtykker i å delta kontakter du Lab386@hotmail.no for å gjøre avtale 
om dato og tidspunkt for oppmøte på IPS, teorifagbygget, hus 5, plan 3. Ved 
ankomst vil du få prøve smertestimulus før du starter eksperimentet og eventuelt 
avgjøre om du vil delta eller ikke. Dersom du ønsker å delta vil du gjennomgå den 
eksperimentelle prosedyren som varer i ca 45 minutter.  
 
Studiedeltakerens ansvar 
Som deltaker i denne studien er det ditt ansvar å lese informasjonen vedrørende 
deltakelse.  
 
Eventuell kompensasjon til dekning av utgifter for deltakere 
Etter gjennomføring av eksperimentet vil du få et gavekort på 200 kr som 
kompensasjon for deltakelse i eksperimentet. 
 
Kapittel B - Personvern, økonomi og forsikring 
 
Personvern 
Opplysninger som registreres om deg er navn, alder, fødselsdato og kjønn. Navn vil 
bli lagret separat fra resultatene som framkommer i eksperimentet og vil bare bli 
brukt for å sende deg rapport på funnene for hele studien etter at studien er fullført 
for alle deltakerne. Navnelister vil bli slettet så snart studien er fullført for alle 
deltakerne. Informasjonen om deg skal kun brukes som beskrevet i hensikten med 
studien. Alle opplysningene vil bli behandlet uten navn og fødselsnummer eller 
andre direkte gjenkjennende opplysninger. En kode knytter deg til dine opplysninger 
og resultater gjennom en navneliste. Det er kun autorisert personell knyttet til 
prosjektet som har adgang til navnelisten og som kan finne tilbake til deg. Det vil 
ikke være mulig å identifisere deg i resultatene av studien når disse publiseres. 
Universitetet i Tromsø ved administrerende direktør er databehandlingsansvarlig. 
 
Rett til innsyn og sletting av opplysninger om deg 
Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger 
som er registrert om deg. Du har videre rett til å få korrigert eventuelle feil i de 
opplysningene vi har registrert. Dersom du trekker deg fra studien, kan du kreve å få 
slettet innsamlede opplysninger, med mindre opplysningene allerede er inngått i 
analyser eller brukt i vitenskapelige publikasjoner.  
Økonomi og Universitetet i Tromsøs rolle 
Studier er finansiert utelukkende gjennom forskningsmidler fra Universitetet i 
Tromsø. Det er ingen økonomiske interessekonflikter som kan påvirke 
gjennomføringen av studien, eller publiseringen av resultatene.  
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Forsikring 
Alle deltakere i denne studien er dekket av Produktansvarsloven og av særskilt 
forsikring for laboratorier ved Institutt for psykologi, UIT. 
Informasjon om utfallet av studien 
Dersom du ønsker det, vil du få tilsendt en skriftlig rapport om resultatene fra denne 
studien så snart alle deltakerne har gjennomført. Dersom du ønsker dette, ber vi deg 
føre opp kontaktadresse på samtykkeerklæringen som vi beholder. 
 
 
Samtykke til deltakelse i studien 
 
 











































Fear of pain questionnaire – III           
 
Instruksjon: Setningene under beskriver smertefulle opplevelser. Les hvert 
spørsmål og tenk på hvor redd du er for å oppleve SMERTEN som er forbundet 
med hver opplevelse. Hvis du aldri har opplevd smerte knyttet til en av 
situasjonene, svar slik du forventer at FRYKTEN ville vært dersom du hadde 
en slik opplevelse. Sett en sirkel rundt tallverdien for å rangere din FRYKT 
FOR SMERTE i forhold til hver opplevelse.  
 
GRAD AV FRYKT 
 
Ikke                    En                   
i det                    god   Veldig  
hele tatt  Litt     del       mye       Ekstrem 
 
1               2          3         4             5               1. Være med i en bilulykke.  
 
1               2          3         4             5                2. Bite deg i tungen mens du spiser.  
 
1               2          3         4             5                3. Brekke armen.  
 
1               2          3         4             5                4. Skjære deg i tungen på en konvolutt.  
 
1               2          3         4             5                5. Noe tungt treffer deg i hodet.  
 
1               2          3         4             5                6. Brekke en fot.  
 
1               2          3         4             5                7. Slå deg på et følsomt sted på albuen.  
 
1               2          3         4             5                8. Ta en blodprøve med en sprøyte.  
 
1               2          3         4             5                9. Noen slenger en tung bildør over hånden                                              
din.  
 
1               2          3         4             5              10. Ramle ned en betongtrapp.   
 
1               2          3         4             5              11. Få en injeksjon med en sprøyte i armen.  
 
1               2          3         4             5              12. Brenne fingrene på en fyrstikk.  
 
1               2          3         4             5              13. Brekke nakken.  
 
1               2          3         4             5              14. Få en injeksjon med en sprøyte i hoften.  
 
1               2          3         4             5              15. Få en flis i fotsålen og deretter få den 
fjernet  
                                                                                   med pinsett.  




                                                                               Fortsetter på neste side. 
 
 
GRAD AV FRYKT 
 
 
Ikke                     En                   
i det                    god  Veldig  
hele tatt  Litt     del      mye       Ekstrem 
 
1               2          3         4             5                 16. Få et objekt som sitter fast i øyet ditt 
fjernet av        
                                                                                en lege.  
 
1               2          3         4             5                 17. Få en injeksjon med en sprøyte i 
munnen.                     
 
1               2          3         4             5                 18. Bli brent i ansiktet av en sigarettglo.           
 
1               2          3         4             5                 19. Kutte en finger på papir.          
 
1               2          3         4             5                 20. Måtte sy sting i leppa.               
 
1               2          3         4             5                 21. Få en vorte på foten fjernet av en 
lege med                      
                                                                                et skarpt instrument.  
 
1               2          3         4             5                 22. Kutte deg med en skarp barberhøvel 
når du                                              
                                                                                barberer deg.   
 
1               2          3         4             5                 23. Svelge en varm drikk før den er 
avkjølt.                  
 
1               2          3         4             5                 24. Få sterk såpe i øynene mens du dusjer 
eller               
                                                                                bader.  
 
1               2          3         4             5                 25. Få en dødelig sykdom som gir deg 
daglig   
                                                                                smerte.            
 
1               2          3         4             5                 26. Få trekt en tann.                  
 
1               2          3         4             5                 27. Kaste opp flere ganger på grunn av                         
                                                                                matforgiftning.   
 
1               2          3         4             5                 28. Få sand eller støv blåst inn i øynene.                       
 
1               2          3         4             5                 29. Bli boret i en tann.           
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1               2          3         4             5                 30. Få muskelkrampe.                                      
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Appendix D 
PANAS (oversatt av Peter Lyby) 
De følgende ordene beskriver ulike følelser og emosjoner. 
 
Vær vennlig å angi hvordan du føler deg akkurat nå ved å tegne en sirkel rundt det 
svaralternativet som passer best for hver følelse. 
 
1 = Svært lite eller ikke i det hele tatt 
2 = Litt 
3 = Moderat 
4 = En god del 
5 = Ekstremt (svært mye) 
 
(1) = Svært lite 
eller ikke i det 
hele tatt 














En god del 
Ekstremt 
(svært mye) 
1. Interessert 1 2 3 4 5 
2. Bekymret 1 2 3 4 5 
3. Oppstemt 1 2 3 4 5 
4. Oppskaket 1 2 3 4 5 
5. Sterk 1 2 3 4 5 
6. Skyldig 1 2 3 4 5 
7. Redd 1 2 3 4 5 
8. Fiendtlig 1 2 3 4 5 
9. Entusiastisk 1 2 3 4 5 
10. Stolt 1 2 3 4 5 
11. Irritabel 1 2 3 4 5 
12. Årvåken 1 2 3 4 5 
13. Skamfull 1 2 3 4 5 
14. Inspirert 1 2 3 4 5 
15. Nervøs 1 2 3 4 5 
16. Bestemt 1 2 3 4 5 
17. Oppmerksom 1 2 3 4 5 
18. Urolig 1 2 3 4 5 
19. Aktiv 1 2 3 4 5 
20. Engstelig 1 2 3 4 5 
 
